The results of experiments in mice models were "astounding," said biochemist Suzanne Pfeffer of Stanford University.

Stanford researchers discovered that dialing down an overactive enzyme, LRRK2, can regrow lost cellular “antennae” in key ...

Inhibiting an overabundant enzyme saved a key component of a brain signaling pathway that is vital for motor control in a ...

Currently dopamine replacement medications, like levodopa and dopamine agonists, are the primary treatment for Parkinson's ...

Neurodegenerative diseases like Parkinson’s and Alzheimer’s affect millions of people and are becoming more common as the ...

A cancer immunotherapy may slow Parkinson’s disease by blocking the spread of harmful brain proteins, Johns Hopkins researchers found.

Inhibition of LKKR2 may rescue neurons that are dying due to a type of Parkinson’s disease that is caused by a single genetic mutation.

Scientists from the University of Copenhagen have uncovered a critical clue about what causes Parkinson’s disease, offering ...

While the research is still in early stages, it’s an exciting step forward. Most current treatments for Parkinson’s only help ...

By focusing on twins and patients with lupus and Parkinson’s disease, a Mexican consortium is generating critical data to ...

Kinetic measures of a cerebrospinal fluid (CSF) biomarker test predicted cognitive decline in Parkinson's disease and ...

Scientists have achieved a major breakthrough in Parkinson's disease research, identifying a brain protein that may unlock new possibilities for treatment, a new research has revealed.